| Primary | Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Selpercatinib in Plasma (Part 1) | PK: AUClast of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hour*nanogram per milliliter (h*ng/mL) | | PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 milligram (mg) of [14C]-Selpercatinib (containing approximately 40 µCi). |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | PK: AUClast of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity | PK: AUClast of [14C] Selpercatinib in plasma and whole blood | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | h*ng equivalents per gram (h*ng Eq/g) | | PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma (Part 1) | PK: AUC0-inf of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hours*nanogram per milliliter (h*ng/mL) | | PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: AUC0-inf of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity | PK: AUC0-inf of [14C] Selpercatinib in plasma and whole blood | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | h*ng Eq/g | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib in Plasma (Part 1) | PK: AUC0-24 of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | h*ng/mL | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: (AUC0-24) of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity | PK: AUC0-24 of [14C] Selpercatinib in plasma and whole blood | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | h*ng Eq/g | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma (Part 1) | PK: Cmax of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng/mL | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Cmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity | PK: Cmax of [14C] Selpercatinib in plasma and whole blood | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | nanogram equivalents per gram (ng Eq/g) | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Time to Reach Cmax (Tmax) of Selpercatinib in Plasma (Part 1) | PK: Tmax of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Median | Full Range | hour (h) | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| | |
| Primary | PK: Tmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity | PK: Tmax of [14C] Selpercatinib in plasma and whole blood | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Median | Full Range | h | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma (Part 1) | PK: t½ of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Mean | Standard Deviation | h | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: t½ of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity | PK: t½ of [14C] Selpercatinib in plasma and whole blood | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Mean | Standard Deviation | h | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Apparent Systemic Clearance (CL/F) of Selpercatinibin Plasma (Part 1) | PK: CL/F of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liter per hour (L/h) | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Selpercatinib in Plasma (Part 1) | PK: Vz/F of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Liter (L) | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Plasma Selpercatinib/Total Radioactivity AUC0-24 Ratio (Part 1) | PK: AUC0-24 of Selpercatinib in plasma/AUC0-24 of total radioactivity in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: Blood/Plasma Total Radioactivity AUC0-24 Ratio (Part 1) | PK: AUC0-24 of total radioactivity in whole blood/AUC0-24 of total radioactivity in whole blood | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose | | | | ID | Title | Description |
|---|
| OG000 | [14C]-Selpercatinib - Part 1 | Participants received a single oral dose of 165 mg of [14C]-Selpercatinib (containing approximately 40 µCi). |
| |
| Primary | PK: AUClast of Selpercatinib in Plasma (Part 2) | PK: AUClast of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | hour*picogram per mL (h*pg/mL) | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: AUClast of [14C] Selpercatinib in Plasma (Part 2) | PK: AUClast of [14C] Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | h*pg/mL | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: AUC0-inf of Selpercatinib in Plasma (Part 2) | PK: AUC0-inf of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | h*pg/mL | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: AUC0-inf of [14C] Selpercatinib in Plasma (Part 2) | PK: AUC0-inf of [14C] Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | h*pg/mL | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: Cmax of Selpercatinib in Plasma (Part 2) | PK: Cmax of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng/mL | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: Cmax of [14C] Selpercatinib in Plasma (Part 2) | PK: Cmax of [14C] Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng/mL | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: Tmax of Selpercatinib in Plasma (Part 2) | PK: Tmax of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Median | Full Range | h | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: Tmax of [14C] Selpercatinib in Plasma (Part 2) | PK: Tmax of [14C] Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Median | Full Range | h | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: t½ of Selpercatinib in Plasma (Part 2) | PK: t½ of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Mean | Standard Deviation | h | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: t½ of [14C] Selpercatinib in Plasma (Part 2) | PK: t½ of [14C] Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Mean | Standard Deviation | h | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: CL/F of Selpercatinib in Plasma (Part 2) | PK: CL/F of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L/h | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: Systemic Clearance (CL) of [14C] Selpercatinib in Plasma (Part 2) | PK: CL of [14C] Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L/h | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: Vz/F of Selpercatinib in Plasma (Part 2) | PK: Vz/F of Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: Volume of Distribution During the Terminal Phase (Vz) of [14C] Selpercatinib in Plasma (Part 2) | PK: Vz of [14C] Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L | | Pre-dose up to 168 hour post-dose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: Volume of Distribution at Steady State (Vss) of [14C] Selpercatinib in Plasma (Part 2) | PK: Vss of [14C] Selpercatinib in plasma | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |
| Primary | PK: Absolute Bioavailability (F) of Selpercatinib in Plasma (Part 2) | Absolute bioavailability was determined by comparing the plasma exposure of LOXO-292 following oral dosing with the plasma exposure of [14C]-LOXO-292 following IV dosing. | All participants who received at least 1 dose of study drug and had evaluable PK data. | Posted | | Geometric Mean | Geometric Coefficient of Variation | Ratio | | Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose | | | | ID | Title | Description |
|---|
| OG000 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Participants received a single oral dose of 160 mg Selpercatinib followed by a single dose of <100 µg of [14C]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV). |
| |